
CCHR Warns Against $7 Billion Psychedelic Drug Push to Treat Mental Issues
Rev. Shaw from the group’s Racism Task Force also cautions African Americans against offers to treat racial trauma with psychedelics, citing history of racist psychiatric…
Rev. Shaw from the group’s Racism Task Force also cautions African Americans against offers to treat racial trauma with psychedelics, citing history of racist psychiatric…
Current research into psychedelic drugs in the treatment of mental disorders is heading in a dangerous “Brave New World” direction. With a history of psychiatric-intelligence…
Low doses of psychedelic drugs, including lysergic acid diethylamide (LSD), ketamine, and psilocybin, may reduce clinical symptoms in patients with depression, anxiety, obsession-compulsive disorders (OCDs), and chronic pain, without inducing depersonalization or hallucinations, according to a new Perspectives article published online August 18 in Nature Reviews Neuroscience.